The upgrade of Passage Bio to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and ...

PASSAGE BIO, INC. earnings at a glance (GAAP ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

Passage Bio, Inc. (NASDAQ:PASG – Free Report) – Equities research analysts at Wedbush lifted their Q1 2025 earnings per share (EPS) estimates for shares of Passage Bio in a research report ...

Passage Bio (NASDAQ:PASG – Get Free Report) is projected to announce its earnings results before the market opens on Monday, March 3rd. Analysts expect the company to announce earnings of ($0.21 ...

Passage Bio, Inc. (NASDAQ:PASG – Free Report) – Equities researchers at Wedbush issued their FY2029 EPS estimates for Passage Bio in a research note issued to investors on Tuesday, March 4th.

Earnings Estimate Revisions for Passage Bio For the fiscal year ending December 2025, this company is expected to earn -$0.69 per share, which is a change of 35.5% from the year-ago reported number.

A replay of the presentation will be available for 30 days following the event. Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of ...